articleThe LancetJan 11, 2013Closed access

Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial

Cincinnati Children's Hospital Medical Center · Royal Sussex County Hospital · +10 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

878
total citations
FWCI
52.31
Percentile
100%
References
32
Citations per year

Authors

17

Topics & keywords

Keywords
  • Tuberous sclerosis
  • Everolimus
  • Lymphangioleiomyomatosis
  • Angiomyolipoma
  • Medicine
  • Placebo
  • Clinical endpoint
  • Internal medicine
No related works found for this paper.